ROS1 (G2101A)

ROS1 · Variant type: point · HGVS: p.G2101A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Repotrectinib	99.7%	0.3%	84.21
2	Entrectinib	99.6%	0.4%	93.69
3	Gilteritinib	99.5%	0.5%	88.97
4	Lazertinib	99.3%	0.7%	97.47
5	Pacritinib	98.7%	1.3%	88.64
6	Pralsetinib	97.9%	2.1%	93.43
7	Alpelisib	95.5%	4.5%	97.22
8	Defactinib	94.7%	5.3%	92.68
9	Fedratinib	92.8%	7.2%	96.21
10	Tivozanib	88.0%	12.0%	92.42
11	Abemaciclib	85.8%	14.3%	91.48
12	Capmatinib	80.2%	19.8%	99.75
13	Tenalisib	80.0%	20.0%	97.98
14	Darovasertib	74.0%	25.9%	96.99
15	Selpercatinib	70.7%	29.3%	96.72
16	Avapritinib	63.3%	36.7%	97.73
17	Pirtobrutinib	55.5%	44.5%	99.49
18	Sunitinib	55.0%	45.0%	91.73
19	Vandetanib	37.8%	62.2%	95.74
20	Neratinib	34.4%	65.6%	93.18
21	Upadacitinib	33.4%	66.6%	97.98
22	Futibatinib	33.4%	66.6%	98.48
23	Pexidartinib	28.0%	72.0%	99.49
24	Infigratinib	17.7%	82.3%	98.24
25	Pemigatinib	17.4%	82.6%	98.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Repotrectinib	99.7%	—	—
Entrectinib	99.6%	—	—
Gilteritinib	99.5%	—	—
Lazertinib	99.3%	—	—
Pacritinib	98.7%	—	—
Pralsetinib	97.9%	—	—
Alpelisib	95.5%	—	—
Defactinib	94.7%	—	—
Fedratinib	92.8%	—	—
Tivozanib	88.0%	—	—
Abemaciclib	85.8%	—	—
Capmatinib	80.2%	—	—
Tenalisib	80.0%	—	—
Darovasertib	74.0%	—	—
Selpercatinib	70.7%	—	—
Avapritinib	63.3%	—	—
Pirtobrutinib	55.5%	—	—
Sunitinib	55.0%	—	—
Vandetanib	37.8%	—	—
Neratinib	34.4%	—	—
Upadacitinib	33.4%	—	—
Futibatinib	33.4%	—	—
Pexidartinib	28.0%	—	—
Infigratinib	17.7%	—	—
Pemigatinib	17.4%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.6ms